News | OSF Breakthrough Treatment Center

Jump ARCHES

OSF Partners with University of Illinois to Advance Easier Lung Cancer Screening and Better Tools for Cancer Survivors

AI Early Detection

OSF and Illinois State Launch AI Research to Improve Lung Cancer Risk Detection from Medical Records

3D rendering of Antibody-Drug Conjugates (ADCs) in a biological environment

Phase 1 Lung, Ovarian, and Endometrial Trial

OSF HealthCare Cancer Institute Opens Phase 1 Study of New Targeted Therapy for Advanced Lung, Ovarian, and Endometrial Cancers

3D representation of a pan ras inhibitor in a biological environment

Expanded Access Program (EAP)

OSF HealthCare Cancer Institute Offers Expanded Access to Investigational Therapy for Metastatic Pancreatic Cancer

3D rendering of Antibodies attaching to ovarian cancer

Phase 3 Ovarian Cancer Trial

OSF HealthCare Cancer Institute Opens Phase 3 Study of New Targeted Therapy for Platinum-Resistant Ovarian Cancer

3D rendering of Antibody in a biological environment

Phase 2 Liver Cancer Trial

OSF HealthCare Cancer Institute Opens Phase 2b Trial fo Novel Combination Therapy for Advanced Liver Cancer

3D rendering of Antibody-Drug Conjugates (ADCs) in a biological environment

Phase 1 Lung Cancer Trial

OSF HealthCare Cancer Institute Opens First-in-Human Phase 1 Trial of New Targeted Therapy for Advanced Lung Cancer

Side-by-side composite: Professional portrait of Dr. Jun Zhang, MD, PhD (left), wearing glasses and a suit, next to a colorful microscopic pathology image of lung cancer tissue stained in purple, black, and teal highlighting cellular structures and potential biomarkers (right).

ASCO 2026

Dr. Jun Zhang Presents Lung Cancer Screening Improvement Study at 2026 ASCO Annual Meeting

3D rendering of a representation of a KRAS Inhibitor

Phase 1 Non-Small Cell Lung Cancer Trial

OSF HealthCare Cancer Institute Begins Phase 1 Trial Exploring New KRAS-Targeted Treatment for Advanced Lung Cancer

3D rendering of an Antibody-Drug Conjugate (ADC) mechanism

Phase 1 Neuroendocrine Cancer Trial

OSF HealthCare Cancer Institute Opens Phase 1b/2 Trial of New Therapy for Advanced Neuroendocrine Tumors

3D rendering of an Antibody-Drug Conjugate (ADC) mechanism

Phase 1 Ovarian & Endometrial Cancer Study

OSF HealthCare Cancer Institute Opens Phase 1 Study of New Targeted Therapy for Advanced Ovarian and Endometrial Cancers

Portrait of Dr. James L. McGee, MD, SM, Radiation Oncologist, smiling while wearing a white lab coat and green tie, next to an exterior view of the modern OSF HealthCare Cancer Institute building.

A Message from President Dr. McGee

A Defining Moment in Advancing Cancer Care

Conceptual scientific illustration for a Phase 1b clinical trial of gilteritinib in advanced ALK-positive non-small cell lung cancer: a glowing human lung with highlighted cancer cells in deep space, symbolizing precision-targeted therapy research at OSF HealthCare Cancer Institute.

Phase 1 Lung Cancer Study

OSF HealthCare Cancer Institute Opens Phase 1b ALK-Positive Non-Small Cell Lung Cancer Research Study

3D microscopic illustration of immune cells attacking cancer cells, with antibodies binding to tumor cell surfaces in a vibrant cellular environment

Endometrial Cancer

OSF HealthCare Cancer Institute Participates in Phase 3 Research Study of Investigational B7-H4-Targeted Therapy for Advanced Endometrial Cancer

3D illustration of antibodies (blue Y-shaped structures) binding to an ovarian cancer cell or tumor mass, depicting targeted immunotherapy attacking cancer cells

Ovarian Cancer

OSF HealthCare Cancer Institute Participates in Phase 2 Research Study of Investigational Antibody-Drug Conjugate Combination for Newly Diagnosed Advanced-Stage Ovarian Cancer

3D illustration of PARP-1 Inhibitor

Phase 1 Relapsed Ovarian Cancer

OSF HealthCare Cancer Institute Begins Phase 1 Research Study of Investigational PARP1-Specific Inhibitor Combination for Relapsed Ovarian Cancer

alt="Composite image: architectural floor plan of the OSF Healthcare Cancer Institute showing 36 exam rooms, 4 theranostics rooms, treatment areas, waiting, seating, executive suite, and SPECT/CT boundary; paired with 3D molecular models of protein structures in white with orange and yellow binding highlights

Cancer Institute Acceleration

OSF HealthCare expanding OSF Cancer Institute

picture of an OSF Patient whose surgical plan and life was changed by 3D imaging technology

Surgical Advances

3D imaging technology changes surgical plan and life for OSF patient

3D illustration of a targeted antibody drug conjugate

SCLC ADC Phase 3 Study

OSF HealthCare Cancer Institute Begins Phase 3 Research Study of Investigational DLL3-Targeted Antibody-Drug Conjugate for Relapsed Small Cell Lung Cancer

3D molecular model of PARP-1 Inhibitor in orange and red straddling a blue helical membrane structure, illustrating a key receptor or signaling protein targeted in cancer therapies

Phase 1 SCLC Lung Cancer Study

OSF HealthCare Cancer Institute Opens Innovative Phase 1 Study for Relapsed Small Cell Lung Cancer

3D illustration of non-small cell lung cancer cells in blue and purple with green surface projections, clustered in a tumor microenvironment surrounded by normal tissue cells

Phase 1 Lung Cancer Study

OSF HealthCare Cancer Institute Opens Phase 1 Non-small Cell Lung Cancer Research Study

Composite image: professional portrait of a smiling man in a dark suit and tie; paired with 3D molecular visualization of a protein complex with blue helical backbone and colorful clustered domains in purple, blue, and teal

Darren Sigal, MD Joins OSF Cancer Institute’s Breakthrough Treatment Center

3D illustration of antibodies (blue Y-shaped structures) binding to and attacking a cervical cancer cell surrounded by healthy tissue cells

Cervical Cancer

OSF HealthCare Cancer Institute Participates in Phase 4 Research Study for Recurrent or Metastatic Cervical Cancer

alt="3D molecular model of immunotherapy with pink and purple surfaces, gray central domains, and yellow binding sites or ligands protruding from multiple subunits, illustrating a key structure in cancer research or targeted therapy

Phase 1 NSLC Lung Cancer Study

OSF HealthCare Cancer Institute Begins Phase 1 Research Study of Investigational Anchored Immunotherapy for Advanced Non-Small Cell Lung Cancer

alt="Composite image: professional portrait of a Dr. Jun Zhang in glasses and dark suit with patterned tie; paired with 3D visualization of a complex blue neural or molecular network with red-orange highlights, illustrating advanced research in oncology or neuroscience"

OSF HealthCare Cancer Institute Welcomes Dr. Jun Zhang as Vice President of Oncology Research

Bold orange graphic with large white text 'BEAT CANCER' in all caps, featuring logos and text for OSF HealthCare Cancer Institute and Cancer Center at Illinois below

BEAT Cancer

The Cancer Center at Illinois (CCIL) and the OSF HealthCare Cancer Institute (OSF) are joining forces on the Breakthrough Engineering and Advanced Treatment (BEAT) of Cancer Research Initiative

KBStrong & Glioblastoma

KBStrong and OSF are bringing transformational collaboration in the global fight against Glioblastoma home to our community

Honoring Sister Diane Marie

The Sister Diane Marie Gynecological Research Fund within the OSF Breakthrough Treatment at the OSF HealthCare Cancer Institute

Composite image: modern server room with rows of illuminated blue data racks representing high-performance computing; paired with a grid of colorful brain scan images showing axial slices with yellow, green, and red activity or metabolic heatmaps

Artificial Intelligence

OSF Breakthrough Treatment Center is working to use AI to detect brain conditions

3D illustration representing cancer early detection: a prominent cancer cell in orange surrounded by blood cells and a glowing DNA double helix, symbolizing the role of molecular and cellular changes in identifying cancer at its earliest stages

Lung Cancer Screening

OSF Breakthrough Treatment Center helps investigate a revolutionary blood test to improve lung cancer screening

3D molecular model of a large blue tumor or nucleosome-like structure densely covered with filamentous extensions and spherical subunits, representing a key assembly in chromatin or cancer-related molecular research

Pancreatic Breakthroughs

OSF engaged in pioneering NIH research for early detection of pancreatic cancer

3D illustration of invasive cancer cells in red-orange with long tentacle-like protrusions spreading across tissue, depicting tumor invasion and metastasis

Solid Tumors

Investigating biomarker-guided therapies for patients with solid tumors

Abstract circular data visualization with concentric rings of colorful rectangular bars in rainbow hues radiating from a dark center, representing genomic or molecular complexity in cancer research

Children's Breakthroughs

OSF helping build an international undiagnosed and rare disease platform for children

Clinician demonstrating the ProBeam 360° proton therapy gantry, a state-of-the-art radiation treatment machine with blue-lit ring, in a high-tech oncology suite

Proton Therapy

First proton therapy patient at OSF Cancer Institute

3D medical illustration of ovarian cancer: reddish tumor cluster with invasive protrusions growing on the ovary within the uterus and fallopian tube anatomy

Gynecologic Oncology

OSF selected to become a member of the Gynecologic Oncology Group (GOG)

Circular Circos plot visualizing polygenic risk scores: concentric rings of multicolored genomic segments with flowing connections in rainbow hues representing genetic associations and risk variant interactions across the genome

Multi-disease Early Detection

OSF Breakthrough Treatment Center investigating polygenic risk scores

3D illustration of immune cells with long branching extensions surrounding and interacting with a large central cancer cell in orange, depicting an immune response against a tumor

New Hope

OSF HealthCare Unveils Breakthrough Treatment Center: A new center to offer the most promising medical advances and trial options to cancer patients